颈段食管鳞状细胞癌患者同步放化疗的长期临床结果
Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma.
作者信息
Kumabe Atsuhiro, Zenda Sadatomo, Motegi Atsushi, Onozawa Masakatsu, Nakamura Naoki, Kojima Takashi, Daiko Hiroyuki, Shigematsu Naoyuki, Akimoto Tetsuo
机构信息
Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
出版信息
Anticancer Res. 2017 Sep;37(9):5039-5044. doi: 10.21873/anticanres.11919.
BACKGROUND/AIM: We assessed the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervical esophagus.
PATIENTS AND METHODS
We retrospectively analyzed 37 patients treated with definitive CCRT. The patients received radiotherapy at a fraction dose of 2 Gy (total; 60 or 70 Gy) and concurrent chemotherapy. Adjuvant chemotherapy consisted of 1 to 2 cycles of 5-fluorouracil plus cisplatin or nedaplatin.
RESULTS
The median follow-up was 119.0 months, the 10-year overall survival, progression-free survival and laryngectomy-free survival rates were 35.6, 19.9 and 30.2% respectively. In the univariate analysis, T stage (T4 vs. T1-3) was the only prognostic factor for PFS. The most common acute toxicity was leukocytopenia (Grade 3; 27%). As for late toxicities, 4 patients (11%) developed Grade 2 or 3 esophageal strictures.
CONCLUSION
The results of this study demonstrated that CCRT yielded satisfactory clinical outcomes with acceptable toxicities.
背景/目的：我们评估了同步放化疗（CCRT）治疗颈段食管癌鳞状细胞癌患者的疗效和毒性。
患者与方法
我们回顾性分析了37例接受根治性CCRT治疗的患者。患者接受2 Gy分次剂量的放疗（总量；60或70 Gy）及同步化疗。辅助化疗由1至2周期的5-氟尿嘧啶加顺铂或奈达铂组成。
结果
中位随访时间为119.0个月，10年总生存率、无进展生存率和无喉切除术生存率分别为35.6%、19.9%和30.2%。单因素分析中，T分期（T4期与T1-3期）是无进展生存期的唯一预后因素。最常见的急性毒性是白细胞减少（3级；27%）。至于晚期毒性，4例患者（11%）出现2级或3级食管狭窄。
结论
本研究结果表明，CCRT产生了令人满意的临床结果，且毒性可接受。
Zotero 插件